Our laboratory studies the molecular pathogenesis of pediatric sarcomas. We hope that by better understanding the specific genetic alterations that occur in these tumors, we can develop more effective therapies. Currently, the major focus of our studies centers on Ewing's sarcoma, rhabdomyosarcoma, and osteogenic sarcoma. We have identified specific genetic alterations that occur in all of these tumors and are developing novel therapeutic strategies aimed at these tumor specific alterations.

Specifically, we currently have identified an altered growth factor pathway which may be critical for the growth of osteogenic sarcomas. We have therefore begun a study using a compound (Sandostatin LAR®) that interrupts this pathway in recurrent osteosarcoma. The agent we are testing blocks the secretion of a naturally occurring hormone called growth hormone, and thus represents a non-cytotoxic novel therapy for this tumor. For rhabdomyosarcoma and Ewing's sarcoma, tumor specific genetic alterations have been identified that are present only in the tumor cells. We are developing a new protocol aimed at using immunotherapy that targets these tumor specific genetic changes.

Also see T Cell Therapeutics Group
Lee J. Helman, M.D., Molecular Oncology Section

Last Updated: July 26, 2006

NCI Home Page|| NIH Home Page

© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute